Sign up
Pharma Capital

N4 Pharma PLC RNS Release

Nuvec resource changes


RNS Number : 6494H
N4 Pharma PLC
16 November 2018
 

16 November 2018

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Nuvec® resource changes

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, is pleased to announce that it has engaged Melody Janssen PhD under a consultancy contract to lead its internal and external research program for its novel delivery system, Nuvec®.

 

Melody is an Internationally acknowledged expert in virology and immunology and brings a wealth of experience to the Company's research program. Melody has extensive experience of different delivery systems and was formerly Head of R&D and pre-clinical development for Mymetics, a leading biotech company in vaccine development based on a proprietary virosome technology.

 

In conjunction with Melody's appointment, Andrew Leishman will step down as Head of the Nuvec® division with effect from 10 January 2019, to enable him to take up other consultancy positions. Thereafter, he will continue to work with and advise the Company as a consultant.

 

 

Nigel Theobald, CEO of N4 Pharma commented:

 

"We are delighted to welcome Melody to the N4 team and her wealth of experience will be invaluable to help ensure our Nuvec® pharmacology program continues to provide relevant  results for potential collaborators."

 

 

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

Via Alma PR

 

Allenby Capital Limited

James Reeve/Virginia Bull/Asha Chotai

 

Tel: +44(0)203 328 5656

Alma PR

Josh Royston

Robyn Fisher

 

Tel: +44(0)778 090 1979

Tel: +44(0)754 070 6191

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®

Nuvec® has shown to be capable of loading and delivering mRNA and pDNA into cells to the required level needed to generate an immune response. Further work will be undertaken for the direct loading and delivery of peptides and proteins using Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immune response. As these products progress through pre clinical and clinical programs N4 will receive up front and milestone payments and ultimately royalty payments once products reach the market.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCXQLFFVFFXFBX



© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.